[Click eStock] "BioPlus Expected to Achieve Record High Q4 Performance"

Hanyang Securities forecasted on the 20th that BioPlus will achieve its highest-ever performance in the fourth quarter of this year.

Lee Joon-seok, a researcher at Hanyang Securities, stated in a report on the same day, "BioPlus's factory operating rate rose from 63% in the first quarter to 82% in the third quarter, and it is estimated to have recently reached about 90% due to increased orders for HA fillers from clients," adding, "This is an indicator of strong demand for the company's products."

The researcher added, "Despite the company's corporate strength advancing to a new level through business structure reorganization, the stock price remains at historically low levels," and "It is expected to set a new annual record in 2025, especially with additional cosmetics sales planned through GMP certification of the Hainan factory in China."

He said, "The factory expansion to meet the high demand for HA fillers is also in its final stages, and the company is preparing to leap forward as a comprehensive healthcare company by diversifying its business into cosmetics, fillers, and obesity treatments," and predicted, "This year was a time of endurance to lay the foundation for growth, but from next year, these efforts will bear fruit."

He continued, "The restructuring of the distribution system and strengthening of sales strategies, which have been promoted since the first half of the year, will lead to improved performance, and the consolidated results for the fourth quarter are expected to show sales of 23.2 billion KRW and operating profit of 9.57 billion KRW, increases of 43.6% and 52.4% respectively compared to the same period last year."